Figure 1

DUOX1 expression correlates with survival in SKCM patients and decreases in metastatic SKCM. (A) Kaplan–Meier survival analysis of TCGA cohort of early- (I + II + III Clark levels at diagnosis) and late- (IV and V Clark levels at diagnosis) stage SKCM patients according to their DUOX1 transcript levels: first quartile (Low), second and third (Medium) and fourth (High). Early-stage melanoma: Low, n = 22; Medium, n = 59; High, n = 16. Late-stage melanoma: Low, n = 57; Medium, n = 100; High, n = 60. Statistical significance was calculated with Mantel–Cox test. (B) Kaplan–Meier survival analysis of TCGA cohort of SKCM patients according to Clark-level classification at diagnosis: early-stage (I + II + III, n = 99) and late-stage (IV + V, n = 217). Statistical significance was calculated with Mantel–Cox test. (C) DUOX1 transcript levels in primary (n = 102) and metastatic (n = 360) SKCMs from TCGA cohort. Each dot represents a patient, and the mean is also shown. **** p < 0.0001 according to unpaired Student t test. a.u., arbitrary units.